Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

ArQule Inc. (ARQL)

1.66 Down 0.05(2.92%) Apr 17, 4:00PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
ArQule Inc.
19 Presidential Way
Woburn, MA 01801
United States - Map
Phone: 781-994-0300
Fax: 781-376-6019

Index Membership:N/A
Full Time Employees:63

Business Summary 

ArQule, Inc., a clinical-stage biotechnology company, researches and develops cancer therapeutics. Its lead product candidate tivantinib is an inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase 3 clinical trial for the treatment of non-small cell lung and liver cancer; and Phase 2 clinical trial for the treatment of colorectal cancer. The company’s early clinical-stage products include ARQ 092, an inhibitor of the Akt protein kinase; ARQ 087, a multi-kinase inhibitor with pan-fibroblast growth factor receptor activity; ARQ 761, a NQ01 inhibitor; ARQ 621, an inhibitor of the Eg5 kinesin motor protein; and ARQ 736, an inhibitor of the RAF kinases. It has partnership agreement with Daiichi Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. for implementing a clinical development program designed to realize the potential of tivantinib as a single agent; and in combination with other anti-cancer therapies in various disease indications. In addition, the company has research collaboration with Daiichi Sankyo Co., Ltd. to discover therapeutic compounds that selectively inhibit certain kinases in the field of oncology based on its ArQule Kinase Inhibitor Platform (AKIP) technology. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on ArQule Inc.

Corporate Governance 
ArQule Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 6. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 8; Compensation: 7.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Paolo Pucci , 52
Chief Exec. Officer and Director
Mr. Peter S. Lawrence J.D., 51
Pres, Chief Operating Officer, Principal Financial Officer, Gen. Counsel and Sec.
Dr. Brian Schwartz M.D., 52
Chief Medical Officer and Sr. VP of Clinical & Regulatory Affairs
Mr. Robert J. Weiskopf , 63
Principal Accounting Officer, VP of Fin., Corp. Controller and Treasurer
Mr. William B. Boni , 62
VP of Investor Relations & Corp. Communications
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders